secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000939767-24-000116
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q2 revenue $637M, GAAP EPS $0.77; $500M buyback, FDA accepts cabozantinib sNDA
--------------------------------------------------------------------------------

- Total revenues $637.2M vs $469.8M YoY; cabozantinib U.S. net product revenues $437.6M.
- GAAP diluted EPS $0.77 vs $0.25 YoY; non-GAAP diluted EPS $0.84 vs $0.31.
- FDA accepted sNDA for cabozantinib in advanced NET; target action date April 3, 2025.
- Earned $150M milestone from Ipsen; completed $450M buyback; new $500M buyback authorized through 2025.
- Discontinued XB002 development; plans to initiate phase 3 for zanzalintinib in NET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000116/0000939767-24-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976724000116/exel-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000939767-24-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer